One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization

References

• Cheng ZJ, Shan J. Novel coronavirus: where we are and what we know. Infection. 2019;2020(48):155–163.
   Google Scholar
• Walls AC, Tortorici MA, Bosch BJ, et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature. 2016;531:114–117.
   PubMed Web of Science ®Google Scholar
• Walls AC, Tortorici MA, Snijder J, et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A. 2017;114:11157–11162.
   PubMed Web of Science ®Google Scholar
• Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–650.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956–963.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369:650–655.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jackson CB, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11:6013.
   PubMed Web of Science ®Google Scholar
• Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–121.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–827. e19.
   PubMed Web of Science ®Google Scholar
• CDC. Science brief: emerging SARS-CoV-2 variants. 2021.
   Google Scholar
• Peter Horby CH, Nick Davies, John Edmunds, et al. NERVTAG note on B.1.1.7 severity. SAGE meeting report.
   Google Scholar
• Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397:452–455.
   PubMed Web of Science ®Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021.
   Google Scholar
• Slifka MK, Amanna IJ. Role of multivalency and antigenic threshold in generating protective antibody responses. Front Immunol. 2019;10:956.
   PubMed Web of Science ®Google Scholar
• Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36:4768–4773.
   PubMed Web of Science ®Google Scholar
• Jardine JG, Kulp DW, Havenar-Daughton C, et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2016;351:1458–1463.
   PubMed Web of Science ®Google Scholar
• Brouwer PJM, Brinkkemper M, Maisonnasse P, et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. 2021;184:1188–1200.
   PubMed Web of Science ®Google Scholar
• Walls AC, Fiala B, Schafer A, et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 2020;183:1367–1382.
   PubMed Web of Science ®Google Scholar
• Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12:372.
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38:7892–7896.
   PubMed Web of Science ®Google Scholar
• Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21:1065–1070.
   PubMed Web of Science ®Google Scholar
• He L, Cheng Y, Kong L, et al. Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep. 2015;5:12501.
   PubMed Web of Science ®Google Scholar
• Sliepen K, Ozorowski G, Burger JA, et al. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology. 2015;12:82.
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Bu W, Joyce MG, et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell. 2015;162:1090–1100.
   PubMed Web of Science ®Google Scholar
• Powell AE, Zhang K, Sanyal M, et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. ACS Cent Sci. 2021;7:183–199.
   PubMed Web of Science ®Google Scholar
• Saunders KO, Lee E, Parks R, et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021;594:553–559.
   PubMed Web of Science ®Google Scholar
• Martinez DR, Schafer A, Leist SR, et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021;373(6558):991–998. DOI: https://doi.org/10.1126/science.abi4506.
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN, Wang N, Pallesen J, et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep. 2018;8:15701.
   PubMed Web of Science ®Google Scholar
• Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017;114:E7348–E7E57.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sundling C, Wilson R, et al. High-resolution longitudinal study of HIV-1 Env vaccine-elicited B cell responses to the virus primary receptor binding site reveals affinity maturation and clonal persistence. J Immunol. 2016;196:3729–3743.
   PubMed Web of Science ®Google Scholar
• Wang Y, O’Dell S, Turner HL, et al. HIV-1 cross-reactive primary virus neutralizing antibody response elicited by immunization in nonhuman primates. J Virol. 2017;91:e00910–e00917.
   Web of Science ®Google Scholar
• Wang Y, Howell KA, Brannan J, et al. Prominent neutralizing antibody response targeting the ebolavirus glycoprotein subunit interface elicited by immunization. J Virol. 2021;95(8):e01907-20.
   Web of Science ®Google Scholar
• Bangaru S, Ozorowski G, Turner HL, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370:1089–1094.
   PubMed Web of Science ®Google Scholar
• Ogura T, Iwasaki K, Sato C. Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. J Struct Biol. 2003;143:185–200.
   Web of Science ®Google Scholar
• Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370:1110–1115.
   PubMed Web of Science ®Google Scholar
• Shackelford C, Long G, Wolf J, et al. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol. 2002;30:93–96.
   PubMed Web of Science ®Google Scholar
• Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol. 2004;32:126–131.
   PubMed Web of Science ®Google Scholar
• Renne R, Brix A, Harkema J, et al. Proliferative and nonproliferative lesions of the rat and mouse respiratory tract. Toxicol Pathol. 2009;37:5s–73s.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–124.
   PubMed Web of Science ®Google Scholar
• ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3:e237.
   PubMed Web of Science ®Google Scholar
• Tostanoski LH, Wegmann F, Martinot AJ, et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med. 2020;26:1694–1700.
   PubMed Web of Science ®Google Scholar
• Bernal J L, Andrews N, Gower C, et al. Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–594.
   PubMed Web of Science ®Google Scholar
• Joyce MG, King HAD, Naouar IE, et al. Efficacy of a broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine in nonhuman primates. bioRxiv. 2021. doi: https://doi.org/10.1101/2021.03.24.436523
   Google Scholar
• Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020;369:812–817.
   PubMed Web of Science ®Google Scholar
• Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607.
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583:834–838.
   PubMed Web of Science ®Google Scholar
• Yahalom-Ronen Y, Tamir H, Melamed S, et al. A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11:6402.
   PubMed Web of Science ®Google Scholar
• Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–694.
   PubMed Web of Science ®Google Scholar
• Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22:72–73.
   PubMed Web of Science ®Google Scholar
• Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52:154–164.
   PubMed Web of Science ®Google Scholar
• Prill MM, Iwane MK, Edwards KM, et al. Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J. 2012;31:235–240.
   PubMed Web of Science ®Google Scholar
• Ledford H. Coronavirus reinfections: three questions scientists are asking. Nature. 2020;585:168–169.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–340.
   PubMed Web of Science ®Google Scholar
• Khan S, Nakajima R, Jain A, et al. Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.24.006544
   Google Scholar
• Cohen SA, Kellogg C, Equils O. Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. Hum Vaccin Immunother. 2020: 1–4. 2021 Jan 2;17(1):84–87.
   Web of Science ®Google Scholar
• Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78:12672–6.
   PubMed Web of Science ®Google Scholar
• Hashem AM, Algaissi A, Agrawal AS, et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East Respiratory Syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. J Infect Dis. 2019;220:1558–1567.
   PubMed Web of Science ®Google Scholar
• Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12:2351–2356.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168:1114–1125.
   PubMed Web of Science ®Google Scholar